Incidence of Colorectal Cancer in Southwest China: Based on SCC Database

To evaluate recent trends in CRC incidence, treatment, and survival in the Southwest China.

Study Overview

• Status: Completed
• Conditions: Colorectal Cancer
• Intervention / Treatment: Other: treatment

Detailed Description

The epidemiological feature of colorectal cancer (CRC) showed different trends among countries. Studying the epidemiological and management characteristics between China and the US has important implications for understanding the current status of cancer occurrence, treatment and survival. we established the Southwest China Colorectal (SCC) database, aiming to provide reference information on the diagnosis and management of CRC in China.

• Study Type: Observational
• Enrollment (Actual): 5838

Contacts and Locations

Study Locations

• China
  • Sichuan
    • Chendu, Sichuan, China, 640001
      • West China Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients who were diagnosed with CRC were included

Description

Inclusion Criteria:

1. Clinical diagnosis of colorectal cancer;
2. Received treatment in medical institutions;
3. Regular follow-up after the diagnosis.

Exclusion Criteria:

Patients who lost to follow-up

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
CRC cases	Other: treatment; the actual treatment CRC patients have reveived

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survival	Overall survival (OS) untile the end of follow up	From inclusion until date of death from any cause, or untile the 2023-10-31

Collaborators and Investigators

• Sponsor: West China Hospital
• Investigators: Study Chair: Ziqiang Wang, West China Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2014
• Primary Completion (Actual): December 31, 2017
• Study Completion (Actual): October 31, 2023

Study Registration Dates

• First Submitted: December 6, 2023
• First Submitted That Met QC Criteria: December 14, 2023
• First Posted (Estimated): December 15, 2023

Study Record Updates

• Last Update Posted (Estimated): December 15, 2023
• Last Update Submitted That Met QC Criteria: December 14, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms
• Other Study ID Numbers: CRC-2023

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No